Various pathophysiological changes caused by obesity are closely associated with the high incidence of cardiovascular disease (CVD). Modern medicine emphasizes prevention as the priority and advocates proactive intervention before disease onset. For metabolic diseases such as obesity, lifestyle intervention is the cornerstone, while drug research and development has long focused on weight control by suppressing […]
Tag: diabetes treatment
Beyond Traditional MRAs: The Unique Value and Application Prospects of Finerenone in Primary Aldosteronism
Primary aldosteronism (PA) is characterized by excessive aldosterone secretion, hypertension, and hypokalemia. Long‑term hyperaldosteronism can induce damage to multiple target organs including the heart, kidneys, and blood vessels, significantly increasing the risk of cardiovascular events. As one of the important clinical manifestations of PA, hypokalemia indicates severe disease and poor prognosis. Therefore, correcting hypokalemia and […]
Does the “2+N Systematic Therapy” Make Type 2 Diabetes Remission Possible?
For many people, a diagnosis of type 2 diabetes mellitus (T2DM) means lifelong medication, strict glucose control, and constant risk of complications. In recent years, however, the concept of diabetes remission has quietly changed clinical practice: it is not a cure, but scientific intervention that maintains blood glucose at a non-diabetic level long-term without medication, […]
Substantial Progress Made in Innovative Treatments for Diabetic Retinopathy
Substantial and ongoing advances have been achieved in innovative therapeutic approaches for diabetic retinopathy (DR).The latest breakthroughs are highlighted in the following areas:Nano-Drug Delivery Technologies Break Through the Blood-Retinal BarrierTargeting the pain point of repeated intravitreal injections required by traditional anti-VEGF drugs,nano-drug delivery systems have achieved critical breakthroughs.The TAT-iRGD dual-targeting nano eye drops developed by […]
Innovations in Diabetic Retinopathy Treatment Strategies: Diversified Targets and Long‑Acting Drug Delivery
In recent years, pharmacotherapy for diabetic retinopathy (DR) has gradually shifted from traditional single‑target anti‑VEGF intervention to multi‑pathway coordinated regulation.Evidence‑based medical data for the bispecific antibody faricimab (Ang‑2/VEGF‑A dual inhibitor) in DR treatment continues to accumulate.Post hoc analyses of the YOSEMITE/RHINE trials revealed that faricimab significantly enhances vascular stability compared with aflibercept, and the injection […]
Professor Ye Jianping: Type 2 Diabetes Roots in Excess Energy
At a public conference, Professor Ye Jianping from the Metabolic Disease Research Center of Zhengzhou University shared a series of studies and conclusions on the mechanistic exploration of type 2 diabetes mellitus (T2DM). He delivered an insightful explanation of the biological mechanisms underlying T2DM pathogenesis and summarized its clinical therapeutic strategies and the mechanisms of […]
I Am Metformin — Do You Know Me?
In the 1950s, my big family — the biguanide class of drugs — was born.My eldest brother is buformin, my second brother is phenformin, and I am the youngest: metformin (generic name).I am one of the most commonly used oral antidiabetic medications.Yet few drugs have traveled such a long and winding road as I have.For […]
IcoSema Leads New Heights in Combination Glucose-Lowering Therapy
Type 2 diabetes mellitus (T2DM) is characterized by complex pathophysiological mechanisms and progressive disease progression. Combination therapy with drugs of different mechanisms of action has become an important treatment strategy recommended by guidelines both domestically and internationally. Following the successful development of weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) formulations and weekly basal insulin formulations, injectable […]
Professor Chen Liming: Say Goodbye to Daily Dosing Biweekly DPP-4 Inhibitor Provides More Stable Glycemic Control, Higher Patient Satisfaction, and Long-Term Benefits
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease. Stable glycemic control is critical not only for quality of life—including daily energy, appetite, and sleep—but also for preserving islet function and preventing long-term complications. As the 2026 American Diabetes Association (ADA) guidelines further expand the eligible population for continuous glucose monitoring (CGM), precise evaluation […]
Professor Andreas Liebl, Diabetes and Metabolism Center Bad Heilbrunn, Germany:New Advances Are Improving Patient Management
In recent years, numerous studies have emerged on the management of type 2 diabetes mellitus (T2DM) and obesity.According to Professor Andreas Liebl, the most noteworthy advances currently come from the development of a new generation of incretin-based drugs, including GLP‑1 receptor agonists, GIP receptor agonists, and in the future, possibly even triple agonists that also […]